Condition
Hepatocellular Carcinoma Resectable clinical trials and research
Research outlook What's coming for Liver cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Hepatocellular Carcinoma Resectable clinical trials that are recruiting, in China. By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer
This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.
-
Monitoring blood for early signs of liver cancer recurrence after treatment
This study is testing if monitoring blood for cancer DNA can help find out sooner if liver cancer comes back after treatment, so doctors can better manage care for patients.
Related topics
Quick answers
How many Hepatocellular Carcinoma Resectable clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.